References of "Evrard, Brigitte"
     in
Bookmark and Share    
Full Text
See detailDevelopment of anti-HPV lipoplexes for the treatment of cervical cancer
Lechanteur, Anna ULg; Furst, Tania ULg; Evrard, Brigitte ULg et al

Conference (2013, December 03)

Detailed reference viewed: 12 (4 ULg)
See detailThe intracellular fate of polycarbonate Polyplexes modulates the efficacy of siRNA
Frère, Antoine ULg; Kawalec, Michal; Peixoto, Paul ULg et al

Poster (2013, December)

Detailed reference viewed: 16 (1 ULg)
Full Text
See detailDevelopment of anti-HPV lipoplexes for the treatment of cervical cancer
Lechanteur, Anna ULg; Furst, Tania ULg; Evrard, Brigitte ULg et al

Conference (2013, October 17)

Detailed reference viewed: 17 (5 ULg)
See detailDevice-based controlled local delivery for the treatment of peritoneal pathologies
Riva, Raphaël ULg; Krier, Fabrice; Defrère, Sylvie et al

Poster (2013, August 18)

This contribution aims at reporting the developpment of a controlled drug delivery system (DDS) dedicated to the treatment of intra-peritoneal pathologies, especially endometriosis. At present time ... [more ▼]

This contribution aims at reporting the developpment of a controlled drug delivery system (DDS) dedicated to the treatment of intra-peritoneal pathologies, especially endometriosis. At present time, endometriosis is generally treated by daily oral absorption of drug with the purpose to improve the life quality of patients by the reduction of the pain caused by endometrial lesions. Nevertheless, deleterious side-effects, mainly infertility, are observed as a consequence of the important amount of absorbed active principle. One main advantage of controlled drug delivery devices, e.g. polymer implants, is to maintain sustained drug release over a prolonged period of time thereby eliminating fluctuations in the drug plasma concentration. Moreover, DDS allows a local release of the drug at a specific area, which significantly decreases the active principle concentration in the body and limits side-effects. The peritoneal cavity is a convenient site for the implantation of a DDS against endometriosis because large parts of lesion are localized in this region. At our knowledge, no application of an implant dedicated to the treatment of endometriosis is reported in the literature, whereas the local controlled release of an active principle presents several advantages compared to systemic administration. In this study, anastrozole (2,2’-[5-1H-1,2,4-triazole-1-yl-methyl)-1,3-phenylene]bis(2-methylpropiononitrile)), a well-known aromatase-inhibiting drug, was selected as active molecule. Typically, two non-biodegradable polymers were tested for the elaboration of an anastrozole loaded intra-peritoneal implant, namely polydimethylsiloxane (PDMS) and poly(ethylene-co-vinyl acetate) (EVA). As preliminary research, the ‘in vivo’ biocompatibility of PDMS and EVA in the intra-peritoneal cavity was confirmed by implantation of PDMS and EVA rod-shaped implants in rats. The kinetic of release was determined ‘in vitro’ and confirmed ‘in vivo’. Besides, the efficiency of the implants was improved by the addition of a polymer membrane, which allowed a controlled release of anastrozole over a period of 400 days. [less ▲]

Detailed reference viewed: 23 (5 ULg)
Full Text
Peer Reviewed
See detailPAT tools for the control of co-extrusion implants manufacturing process
Krier, Fabrice ULg; Mantanus, Jérome; Sacre, Pierre-Yves ULg et al

in International Journal of Pharmaceutics (2013), 458

Hot melt extrusion is a novel pharmaceutical manufacturing process technique. In this study, we identified four Critical Quality Attributes (CQAs) of the implant manufacturing process by hot melt ... [more ▼]

Hot melt extrusion is a novel pharmaceutical manufacturing process technique. In this study, we identified four Critical Quality Attributes (CQAs) of the implant manufacturing process by hot melt extrusion: the implant diameter, the quantity of the Active Pharmaceutical Ingredient (API), the homogeneity distribution of API and the thickness of the membrane. We controlled the implant diameter and the quantity of API in-line with a laser measurement, NIR and Raman spectroscopy, respectively. These two different spectroscopic techniques provided comparable results. In fact, the RMSEC and RMSECV were very close in each PAT technique but NIR spectroscopy was easier to use and less sensitive to external changes. For the control of the homogeneity of API distribution and the thickness of the membrane, we used successfully Raman spectroscopy imaging. These PAT tools help reducing analysis time. [less ▲]

Detailed reference viewed: 35 (17 ULg)
Full Text
Peer Reviewed
See detailEvaluation of a new biocompatible poly(N-(morpholino ethyl methacrylate)-based copolymer for the delivery of ruthenium oligonucleotides, targeting HPV16 E6 oncogene
Reschner, Anca ULg; Shim, Yong Ho; Dubois, Philippe et al

in Journal of Biomedical Nanotechnology (2013), 9

This study investigates the use of a new biocompatible block copolymer poly(2-(dimethylamino)ethyl methacrylate-N-(morpholino)ethyl methacrylate (PDMAEMA-b-PMEMA) for the delivery of a particular ... [more ▼]

This study investigates the use of a new biocompatible block copolymer poly(2-(dimethylamino)ethyl methacrylate-N-(morpholino)ethyl methacrylate (PDMAEMA-b-PMEMA) for the delivery of a particular antisense oligonucleotide targeting E6 gene from human papilloma virus. This antisense oligonucleotide was derivatized with a polyazaaromatic RuII complex which, under visible illumination, is able to produce an irreversible crosslink with the complementary targeted sequence. The purpose of this study is to determine whether by the use of a suitable transfection agent, it is possible to increase the efficiency of the antisense oligonucleotide targeting E6 gene, named Ru-P-4. In a recent study, we showed that Oligofectamine® transfected Ru-P-4 antisense oligonucleotide failed to inhibit efficiently the growth of cervical cancer cell line SiHa, contrarily to the Ru-P-6 antisense oligonucleotide, another sequence also targeting the E6 gene. The ability of PDMAEMA-b-PMEMA to form polyplexes with optimal physicochemical characteristics was investigated first. Then the ability of the PDMAEMA-b-PMEMA/Ru-P-4 antisense oligonucleotide polyplexes to transfect two keratinocyte cell lines (SiHa and HaCat) and the capacity of polyplexes to inhibit HPV16 + cervical cancer cell growth was evaluated. PDMAEMA-b-PMEMA base polyplexes at the optimal molar ratio of polymer nitrogen atoms to DNA phosphates (N/P), were able to deliver Ru-P-4 antisense oligonucleotide and to induce a higher growth inhibition in human cervical cancer SiHa cells, compared to other formulations based on Oligofectamine®. [less ▲]

Detailed reference viewed: 102 (29 ULg)
See detailLe double défi de la nanomédecine
Piel, Géraldine ULg; Evrard, Brigitte ULg

Scientific conference (2012, November 29)

Detailed reference viewed: 19 (2 ULg)
Full Text
See detailCharacterization and transfection experiments of polyplexes targeting HDAC7
Frère, Antoine ULg; Kawalec, Michal; Collard, Laurence ULg et al

Poster (2012, October 22)

Detailed reference viewed: 28 (15 ULg)
Full Text
Peer Reviewed
See detailZelfbehandeling van frequente hoofdpijn : een Belgische apotheekstudie
Mehuys, E; Paemeleire, K; Van Hees, Thierry ULg et al

Conference (2012, September)

Detailed reference viewed: 14 (9 ULg)
Full Text
See detailImplant comprising a core and a tube encasing the core
Donnez, Jacques; Van Langendonkt, Anne; Defrère, Sylvie et al

Patent (2012)

The present invention relates to an implant comprising: - a core material comprising polydimethylsiloxane or at least one hydrogel polymer; - a tube encasing said core material comprising an ethylene ... [more ▼]

The present invention relates to an implant comprising: - a core material comprising polydimethylsiloxane or at least one hydrogel polymer; - a tube encasing said core material comprising an ethylene vinyl acetate polymer or at least one hydrogel polymer; - a sealant for closure of the open ends of said tube comprising polydimethylsiloxane or a mono-, di-, or triacetoxy derivative thereof, or at least one hydrogel polymer; and - at least one active ingredient; wherein said at least one active ingredient is selected from the group comprising celecoxib, sulindac, tamoxifen, oestrogen, oestradiol, ethinyl oestradiol, mestranol, dienogest, norgestrel, levonorgestrel, desogestrel, norgestimate, ethynodiol diacetate, leuprorelin, buserelin, gonrelin, triptorelin, nafarelin, deslorelin, histrelin, and supprelin; and with the proviso that when the sealant is said at least one hydrogelpolymer, the core material comprises polydimethylsiloxane. Furthermore, the invention relates to an implant for use as a medicament. In particular, the invention relates to an implant for use in the treatment of endometriosis. [less ▲]

Detailed reference viewed: 43 (12 ULg)
Full Text
See detailImplant comprising a core and a tube encasing the core
Donnez, Jacques; Van Langendonkt, Anne; Defrère, Stéphanie et al

Patent (2012)

The present invention relates to an implant comprising: - a core material comprising polydimethylsiloxane or at least one hydrogel polymer; - a tube encasing said core material comprising an ethylene ... [more ▼]

The present invention relates to an implant comprising: - a core material comprising polydimethylsiloxane or at least one hydrogel polymer; - a tube encasing said core material comprising an ethylene vinyl acetate polymer or at least one hydrogel polymer; - a sealant for closure of the open ends of said tube comprising polydimethylsiloxane or a mono-, di-, or triacetoxy derivative thereof, or at least one hydrogel polymer; and - at least one active ingredient; with the proviso that when the sealant is said at least one hydrogel polymer, the core material comprises polydimethylsiloxane. Furthermore, the invention relates to an implant for use as a medicament. In particular, the invention relates to an implant for use in the treatment of endometriosis. [less ▲]

Detailed reference viewed: 26 (13 ULg)